PLD1 and PLD2 promote an immunosuppressive tumor microenvironment via CCL19-dependent macrophage polarization and PD-L1 induction
Blocking phospholipase D enzymes shifts immune-suppressive tumors toward immune activation in preclinical models, suggesting a new immunotherapy strategy.
Phospholipase D1 and D2 enzymes drive immune suppression in melanoma by promoting M2-like TAM polarization via CCL19 and inducing PD-L1, while their inhibition shifts the TME toward an immune-activated state in preclinical models. PLD inhibition represents a novel approach to overcome resistance to cancer immunotherapy, though clinical translation requires further validation.
What the study was
- Study design
- Preclinical mechanistic study (syngeneic melanoma model + in vitro)
- Population
- Syngeneic melanoma mouse models; human cell lines
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Exp Mol Med
Why it surfaced
PLD as TME regulator is a novel angle; mechanistic pathway is well-delineated (CCL19/PD-L1/PI3K-Akt-NF-κB). Exp Mol Med (Nature portfolio). Preclinical only; melanoma model without human clinical data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.